In 2020, the global pharmaceutical giant's autoimmune disease business ranked TOP10

2020，，。，。，、、、，2020。2020，。

，、，。

NO.

UCB marketed only one drug Cimzia (certolizumab pegol) in the field of autoimmune diseases for the treatment of rheumatoid arthritis, plaque psoriasis, psoriatic arthritis and other autoimmune drugs disease.

The bimekizumab in the UCB clinical pipeline is also worth looking forward to.

NO.

Eli Lilly’s traditional superior business is not autoimmune diseases, but its influence in this field has continued to increase in recent years.

In 2020, Eli Lilly’s income in the field of autoimmune diseases will be mainly contributed by IL-17A monoclonal antibody Taltz (idtilizumab) and JAK inhibitor Olumiant (baritinib), totaling US$2.

NO.

The field of autoimmune diseases was not originally BMS's dominant business.

In the late-stage product pipeline of BMS, the most concerned drug in the field of self-immunization is undoubtedly the Tyk2 inhibitor Deucravacitinib (BMS-986165).

Traditional JAK inhibitors act on kinase catalytic sites, and it is difficult to achieve high selectivity for a single subtype.

NO.

In 2020, Pfizer, with Xeljanz (tofacitib), Enbrel (etanercept) and Inflectra/Remsima (infliximab), will generate a total of $4.

However, Pfizer has not been a smooth road in the field of self-immunity, or will face more challenges.

Of course, in 2021, Pfizer is expected to usher in the approval of another JAK1 inhibitor, Abrocitinib, in the United States and the European Union.

NO.

Dupixent has become Sanofi's "big brother", with sales revenue of 3.

Duplizumab was jointly developed by Regeneron and Sanofi.
It can selectively inhibit the key signaling pathways IL-4 and IL-13, block the Th2-type inflammatory pathway, and reduce the pathological response of Th2-type inflammation.
On the treatment of Th2-type inflammation-related diseases.
Strictly speaking, Duplizumab has been approved for three indications for atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps.
It is difficult to distinguish the absolute contribution of Duplizumab in the field of autoimmunity.
But it may also be included in the analysis.

It is expected that Dupixent's growth rate will continue.
Therefore, not only in the area of ​​self-immunization, but Sanofi's overall performance growth will be driven by Dupixent.
According to Sanofi’s 2020 financial report, among the products with sales exceeding 1 billion euros, only Dupixent and Aubagio in the self-improvement field have achieved positive growth due to demand growth and price increases.
However, Aubagio’s revenue in 2020 has slightly increased by 2 %.
Sanofi is one of the pharmaceutical giants that have received the most impact from generic drugs in the past two years, but the late-stage clinical products in its pipeline are lackluster.
The BTK inhibitor Tolebrutinib has shown a certain advantage in the battlefield of multiple sclerosis.
The IL-17A/F Nanobody is Sanofi’s future hope.

NO.
5 Amgen

Amgen’s income in the self-immunization field mainly comes from Enbrel (etanercept), Otezla (apster), and adalimumab biosimilar drug Amgevita.
The three drugs contribute US$7.
522 billion to Amgen.

The psoriasis drug Otezla (Apster), which was acquired from Celgene for US$13.
4 billion, will bring Amgen nearly US$2.
2 billion in sales in 2020.
Otezla is currently the only innovative oral and non-biological therapy for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis.
It is expected that Otezla’s revenue will continue to increase and may exceed US$3 billion by 2023.
Otezla's biggest advantage is its safety, which may be challenged by Deucavacitinib.

The adalimumab biosimilar drug Amgevita will achieve 54% growth in 2020, contributing US$331 million.
This growth trend is expected to continue to increase with the end of the original patent protection; on the other hand, the biosimilar drug Uselnumumab After listing, it will continue to expand Amgen's income in the self-immunity field.
In terms of innovative drugs, although Amgen and AstraZeneca have accelerated the application of Tezepelumab in asthma and achieved positive results, as a potential FIC drug targeting TSLP, Tezepelumab is also expected to help Amgen in the field of self-immunization.
After all, TSLP is located upstream of multiple inflammatory signaling pathways, and the indications for atopic dermatitis have progressed to clinical phase II.

NO.
4 Roche

In 2020, Roche’s four innovative drugs in the field of self-immunization will have a total revenue of 10.
105 billion Swiss francs.
Ocrevus (ocrelizumab) and Actemra/RoActemra (tocilizumab) contributed significantly, bringing together approximately 7.
2 billion Swiss francs in revenue.

Ocrevus is a CD20 monoclonal antibody.
It is the first drug that has been clinically proven to have a significant effect on primary progressive multiple sclerosis (PPMS).
It has been approved for two types of multiple sclerosis, RRMS and PPMS.
Compared with rituximab, Ocrevus's ADCC is enhanced by 2-5 times, and CDC is reduced by 3-5 times.
It can more effectively bind to FcγRIIIa low-affinity mutants (expressing FF/FV at position 158).
Another advantage of Ocrevus is that it only needs to be injected once every 6 months after the initial load administration is completed, which greatly improves patient compliance.
Although the epidemic has affected the completion of injections in the hospital, Ocrevus has achieved it.
An increase of 24%, reaching 4.
326 billion Swiss francs.

Tocilizumab will achieve a 32% growth in 2020.
Although it has not been widely approved for use in new coronary pneumonia, it is recommended by multinational guidelines for the treatment of patients with severe COVID-19 in the early treatment, which is also after dexamethasone.
The second drug proved to reduce the mortality rate of the new crown in a large clinical trial, with revenue of 2.
858 billion Swiss francs.

In addition to orelizumab and tocilizumab, Roche's Xolair (omalizumab) and Rituxan (rituximab) in the field of self-immunization also achieved nearly 3 billion Swiss francs in revenue.
However, Rituxan (rituximab) was impacted by biosimilar drugs.
In 2020, sales revenue fell by more than 60%, and the self-immunization field fell by 32%, with revenue of 1.
017 billion Swiss francs.

NO.
3 Novartis

Novartis is the company with the largest number of products among the TOP10 companies in the autoimmune disease business, with sales reaching 11.
118 billion U.
S.
dollars.
Among them, Cosentyx (tokuchiyuumab) and Gilenya (Fingolimod) have a combined revenue of 7 billion U.
S.
dollars.
.
Cosentyx is Novartis's highest-revenue drug, with sales revenue increasing by 13.
0% in 2020 to reach 3.
995 billion U.
S.
dollars.
Gilenya will also usher in the competition of generic drugs.
Sales have shown a downward trend for three consecutive years.
In 2020, sales will drop by 7% again, but still reach 3 billion US dollars.

Novartis has not only deployed more innovative drugs in the field of self-immunity, but also biosimilar drugs have been launched on the market.
Hyrimoz, a similar drug of adalimumab, has been approved in the European Union and the United States.
In the late-stage clinical pipeline, Novartis' IgE monoclonal antibody drug Ligelizumab has shown superior potential in a controlled study with Xolair (omalizumab), and has recently obtained the FDA-approved breakthrough therapy qualification for chronic spontaneous urticaria (CSU) .

NO.
2 Johnson & Johnson

Despite the impact of biosimilar drugs and the danger of patent cliffs, Johnson & Johnson’s autoimmune disease business is in Remicade (infliximab), Stelara (usnumab), Simponi/Simponi Aria (golimumab) and Tremfya (Guselkumab), the revenue in 2020 will still reach 15.
04 billion U.
S.
dollars.

Stelara (Usnuzumab) market performance is extremely strong, sales in 2020 hit a new high, reaching 7.
707 billion US dollars, will face the danger of patent expiration in the next 2-3 years, fortunately there is no biosimilar drug listing application, the growth trend or Sustainable.
Remicade (infliximab) has already suffered the impact of market biosimilar drugs, with sales falling from a peak of 7 billion U.
S.
dollars to 3.
7 billion U.
S.
dollars.
However, the new product Tremfya (gussetizumab) has rapidly grown into a blockbuster.
In 2020, it will achieve a 33% growth again, reaching 1.
347 billion U.
S.
dollars.

NO.
1 AbbVie

In 2020, AbbVie once again ranked top 1 in the field of self-exemption revenue, with sales revenue reaching 22.
153 billion U.
S.
dollars.
AbbVie's dual strategy of raising prices and preventing the listing of biosimilar drugs has enabled Humira (adalimumab) to achieve positive growth again in 2020, returning to US$19.
832 billion, and once again hitting the 20 billion threshold.
Skyrizi (risankizumab) and Rinvoq (upadacitinib) also rose rapidly, contributing a total of US$2.
32 billion.

For many years, AbbVie's advantage in this field has been relying on Humira (adalimumab).
Although it is already facing the swallowing of biosimilar drugs in the global market, in the US market, through patent settlements, Humira's exclusive advantage will continue until 2023, and some institutions have predicted that Humira's sales in 2021 will exceed US$20 billion.
From its launch in 2003 to the end of June 2020, Humira has achieved sales of US$165.
8 billion.

Skyrizi achieved sales revenue of US$1.
590 billion in 2020.
Rinvoq has also achieved a large growth rate exceeding 100% in the past year, reaching US$731 million in 2020.
Upatinib/methotrexate is also the first approved dose Proved head-to-head rheumatoid arthritis treatment superior to adalimumab/methotrexate.
In addition, AbbVie has deployed a variety of drugs in the self-immunization field through various forms, including ABBV-599, Elsubrutinib, BI 655064, ABBV-3373, ABBV-154 and other drugs.
It is foreseeable that other drugs in the self-immunity field will still have a greater difficulty to reproduce the success and brilliance of the Humira level.
It is a strategy to maintain competitiveness by playing a combination of multiple drugs.